Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market.
Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market.